検索に戻る
案件記録

MICROBIAL METABOLITES ON INTESTINAL INFLAMMATION

発明審査中
1閲覧数
81請求項 · 63 独立
§ Ⅰ

案件概要

出願人

CEDARS-SINAI MEDICAL CENTER; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

発明者

Noam JACOB; Stephan R. TARGAN; Kathrin S. MICHELSEN; Erica ALEXEEV

IPC分類

A61K 35/74A61K 45/6C12Q 1/6C12Q 1/6883G1N 33/53G1N 33/68

CPC分類

A61K35/74A61K45/6C12Q1/6C12Q1/6883G1N33/5308G1N33/6863C12Q2600/118C12Q2600/156C12Q2600/158G1N2333/57G1N2800/65G1N2800/50

Provided herein are methods of predicting a likelihood that a subject will develop ileitis, intestinal fibrosis or colitis based on an amount of acetate or acetate-producing bacteria detected in a sample obtained from a subject. Certain genetic risk variants at TNF super-family member 15 (TNFSF15) may also be detected. Methods, systems and kits for treatment of develop ileitis, intestinal fibrosis or colitis are also provided, which include inhibitors of acetate or acetate-producing bacteria, or targeting biologic therapeutics, such as inhibitors of Tumor necrosis factor (TNF)-like cytokine 1A (TL1A).

原文(中国語)

Provided herein are methods of predicting a likelihood that a subject will develop ileitis, intestinal fibrosis or colitis based on an amount of acetate or acetate-producing bacteria detected in a sample obtained from a subject. Certain genetic risk variants at TNF super-family member 15 (TNFSF15) may also be detected. Methods, systems and kits for treatment of develop ileitis, intestinal fibrosis or colitis are also provided, which include inhibitors of acetate or acetate-producing bacteria, or targeting biologic therapeutics, such as inhibitors of Tumor necrosis factor (TNF)-like cytokine 1A (TL1A).

外部リソース